- Home
- RYTM vs ALKS Comparison
RYTM vs ALKS Comparison
Compare RYTM & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- ALKS
- Stock Information
- Founded
- RYTM 2008
- ALKS 1987
- Country
- RYTM United States
- ALKS Ireland
- Employees
- RYTM N/A
- ALKS N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- RYTM Health Care
- ALKS Health Care
- Exchange
- RYTM Nasdaq
- ALKS Nasdaq
- Market Cap
- RYTM 3.8B
- ALKS 4.5B
- IPO Year
- RYTM 2017
- ALKS 1991
- Fundamental
- Price
- RYTM $57.38
- ALKS $30.13
- Analyst Decision
- RYTM Strong Buy
- ALKS Buy
- Analyst Count
- RYTM 12
- ALKS 12
- Target Price
- RYTM $75.42
- ALKS $38.33
- AVG Volume (30 Days)
- RYTM 671.0K
- ALKS 1.9M
- Earning Date
- RYTM 05-07-2025
- ALKS 05-01-2025
- Dividend Yield
- RYTM N/A
- ALKS N/A
- EPS Growth
- RYTM N/A
- ALKS N/A
- EPS
- RYTM N/A
- ALKS 2.09
- Revenue
- RYTM $136,863,000.00
- ALKS $1,513,770,000.00
- Revenue This Year
- RYTM $43.84
- ALKS N/A
- Revenue Next Year
- RYTM $65.62
- ALKS $4.09
- P/E Ratio
- RYTM N/A
- ALKS $14.50
- Revenue Growth
- RYTM 48.88
- ALKS N/A
- 52 Week Low
- RYTM $35.17
- ALKS $22.90
- 52 Week High
- RYTM $68.58
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- RYTM 43.00
- ALKS 51.87
- Support Level
- RYTM $62.69
- ALKS $29.78
- Resistance Level
- RYTM $65.53
- ALKS $31.99
- Average True Range (ATR)
- RYTM 3.04
- ALKS 1.04
- MACD
- RYTM -0.73
- ALKS 0.42
- Stochastic Oscillator
- RYTM 1.14
- ALKS 64.09
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.